Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Polyamine metabolism in ischemia reperfusion injury: common mitochondrial mechanisms and organ-specific differences.

Created on 10 Oct 2026

Authors

Yangqi Chu, Pu Chen, Shangwen Pan, Shiqian Huang, Yun Lin, Yu Wang

Published in

Journal of translational medicine. Volume 24. Issue 1. Aug 24, 2026. Epub Aug 24, 2026.

Abstract

Polyamines are essential polycations that play pivotal roles in various cellular processes, including cell proliferation, redox regulation, protein synthesis, and particularly the maintenance of mitochondrial function. During ischemia/reperfusion injury (I/RI), mitochondrial dysfunction emerges as a common mechanism underlying organ damage. This review systematically explores how polyamine metabolism regulates mitochondrial injury in I/RI, focusing on its impact on mitochondrial homeostasis and exacerbating organ damage through the modulation of reactive oxygen species, calcium homeostasis, mitochondrial membrane potential, and mitophagy. By analyzing polyamine metabolic alterations in the heart, kidney, liver, and brain during I/RI, we observe a common metabolic remodeling characterized by enhanced catabolism, while also identifying organ-specific regulatory responses. Finally, we summarize the potential intervention strategies targeting polyamine metabolism and discuss their translational prospects, offering new insights into therapeutic approaches for I/RI.

PMID:
42855676
Bibliographic data and abstract were imported from PubMed on 10 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 1
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement